Neither Viibryd nor Wellbutrin is definitively "better" for depression with anxiety—both second-generation antidepressants show similar efficacy for major depressive disorder, but Viibryd (vilazodone) has specific evidence for improving anxiety symptoms in depressed patients, while Wellbutrin (bupropion) has a lower risk of sexual dysfunction but may cause more insomnia.
Evidence-Based Treatment Selection
The American College of Physicians guidelines establish that all second-generation antidepressants demonstrate comparable efficacy for treating major depressive disorder, with no clinically significant differences in effectiveness 1. This fundamental principle applies to both vilazodone and bupropion—neither medication is inherently superior for treating the depressive component of your patient's illness.
Specific Considerations for Anxiety Symptoms
Vilazodone's Anxiety Profile
Vilazodone demonstrates specific efficacy for anxiety symptoms in patients with major depressive disorder 2. In post-hoc analyses of phase III trials, 82% of patients had anxious depression, and vilazodone showed statistically significant improvements on the Hamilton Anxiety Rating Scale (mean difference -1.82 vs placebo, P<0.001) and on psychic anxiety symptoms 2. The medication improved both somatic and psychic anxiety manifestations across multiple validated measures 2, 3.
Recent evidence confirms vilazodone is effective across the full spectrum of depressive symptoms and severities, with significant improvements beginning at week 1 and persisting throughout treatment 3, 4.
Bupropion's Anxiety Profile
Recent systematic review evidence (2025) indicates that bupropion provides clinically relevant improvement in anxiety symptoms in adults with MDD, with generally comparable efficacy to SSRIs 5. Importantly, bupropion did not worsen anxiety on validated anxiety measures 5. However, in pooled patient-level analyses, SSRIs showed a modest advantage over bupropion specifically in patients with high baseline anxiety 5.
The evidence for bupropion in anxious depression is lower certainty, as anxiety outcomes were often secondary or exploratory endpoints rather than primary measures 5.
Adverse Effect Profiles: The Critical Differentiator
Since efficacy is comparable, your decision should prioritize adverse effect profiles 1:
Sexual Dysfunction
- Bupropion has significantly lower rates of sexual adverse events than SSRIs (including vilazodone, which is an SSRI) 1
- Vilazodone showed treatment-related sexual function effects similar to placebo in some trials 6, but as an SSRI, carries theoretical risk
Gastrointestinal Effects
- Vilazodone causes higher rates of diarrhea (31% vs 11% placebo) and nausea (26% vs 6% placebo) 6, though most cases are mild
- These are the most common reasons for discontinuation with vilazodone 4
Sleep and Activation
- Bupropion causes more insomnia 5, though generally manageable
- This is particularly relevant if your patient already has sleep disturbance
Weight
Clinical Algorithm for Selection
Choose Vilazodone if:
- Patient has prominent psychic or somatic anxiety symptoms requiring specific anxiolytic effects
- Sexual function is not a primary concern
- Patient can tolerate potential GI side effects
- You want an SSRI mechanism with 5-HT1A partial agonism
Choose Bupropion if:
- Patient prioritizes avoiding sexual dysfunction
- Patient has low energy/psychomotor retardation (bupropion may be activating)
- Anxiety is present but not severe (avoid if high baseline anxiety)
- Patient has insomnia that can be managed or prefers activating effects
- Patient wants to avoid weight gain
Critical Caveats
For patients with very high baseline anxiety, consider an SSRI (like vilazodone) over bupropion 5. The modest SSRI advantage in highly anxious subgroups may be clinically meaningful.
Monitor closely in the first 1-2 weeks for worsening anxiety, agitation, or suicidal ideation with either medication 1. Both carry FDA warnings about increased suicide risk, particularly early in treatment.
Assess response by 6-8 weeks—if inadequate improvement, modify treatment 1. Don't wait longer than this timeframe.
The FDA labels confirm both medications are indicated for MDD 7, 8, with bupropion also approved for seasonal affective disorder.
In practice: Start with the medication that best matches your patient's specific adverse effect tolerance and anxiety severity profile, as efficacy for depression is equivalent.